Combined treatment with citalopram and buspirone: Effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain

Pharmacopsychiatry

Volumn 39, Issue 1, 2006, Pages 1-8

  Syvälahti, Erkka ^a   Penttila J ^b,c   Majasuo, H ^b   Palvimaki E P ^d   Laakso, A ^a,d   Hietala, J ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; KETANSERIN; MESULERGINE; PHOSPHATIDYLINOSITIDE; RADIOLIGAND; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BINDING ASSAY; BRAIN; CHOROID PLEXUS; CONTROLLED STUDY; IMAGE ANALYSIS; IN VITRO STUDY; MALE; NEUROTRANSMISSION; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TRANQUILIZING ACTIVITY;

AMPHETAMINES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; AUTORADIOGRAPHY; BRAIN CHEMISTRY; BUSPIRONE; CEREBRAL CORTEX; CHOROID PLEXUS; CITALOPRAM; ERGOLINES; HYDROLYSIS; IMAGE PROCESSING, COMPUTER-ASSISTED; KETANSERIN; MALE; PHOSPHATIDYLINOSITOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS;

EID: 32544435992     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931470     Document Type: Article

References (61)

1. Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther 1990; 255: 843-857
2. Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-452
3. Ashby CRJ, Edwards E, Wang RY. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 1994; 17: 173-181
4. Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res 2003; 959: 58-67
5. Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995; 9: 41-45
6. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994; 269: 11687-11690
7. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203
8. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997; 87: 534-537, 540
9. Dhaenen H. Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosd 2001; 251: 1176-1180
10. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998; 18: 465-469
11. Dolberg OT, Klag E, Gross Y, Schreiber S. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl) 2002; 161: 404-407
12. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 2000; 35: 144-150
13. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001; 62: 4-11
14. Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull 1993; 29: 457-475
15. Gibson EL, Barnfleld AM, Curzon G. Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology 1994; 33: 457-465
16. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997; 69: 2616-2619
17. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotoninlA receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 1999; 93: 1251-1262
18. Golembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 2000; 52: 441-448
19. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996; 54: 129-141
20. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001; 56: 441-451
21. Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998; 18: 10150-10156
22. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1997; 7: 143-147
23. Hietala J, Salonen I, Lappalainen J, Syvälahti E. Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain. Neurosci Lett 1990; 108: 289-294
24. Hjorth S, Auerbach SB. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology 1994; 33: 331-334
25. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203
26. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993; 231: 223-229
27. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269-271
28. Julius D, MacDermott AB, Axel R, Jessell TM. Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science 1988; 241: 558-564
29. Kennett GA. 5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology (Berl) 1992; 107: 379-384
30. Klimek V, Zak-Knapik J, Mackowiak M. Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J Psychiatry Neurosci 1994; 19: 63-67
31. Kuoppamäki M, Pälvimäki EP, Syvälahti E, Hietala J. 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur J Pharmacol 1994; 255: 91-97
32. Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment. Eur J Pharmacol 1994; 269: 201-208
33. Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993; 245: 179-182
34. Laakso A, Pälvimäki EP, Kuoppamäki M, Syvälahti E, Hietala J. Chronic citalopram and fluoxetine treatments upregulate 5-HT2c receptors in the rat choroid plexus. Neuropsychopharmacology 1996; 15: 143-151
35. Lafaille F, Weiner SA, Suranyi-Cadotte BE. Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. J Psychiatry Neurosci 1991; 16: 209-214
36. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59: 664-668
37. Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19: 268-271
38. Lucaites VL, Nelson DL, Wainscott DB, Baez M. Receptor subtype and density determine the coupling repertoire of the 5-HT2 receptor sub-family. Life Sci 1996; 59: 1081-1095
39. Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sect 1992; 88: 143-156
40. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neu-ropsychiatric disorders. Neuropsychopharmacology 2003; 28: 402-412
41. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003; 116: 107-117
42. Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002; 111: 163-176
43. Okazawa H, Yamane F, Blier P, Diksic M. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. J Neurochem 1999; 72: 2022-2031
44. Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord 2003; 76: 223-227
45. Paxinos G, Watson C. The rat brain in stereotaxic coordinates (4th edition). San Diego, USA: Academic Press, 1998
46. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985; 346: 231-249
47. Peroutka SJ, Howell TA. The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacology 1994; 33: 319-324
48. Petty F, Davis LL, Kabel D, Kramer GL. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. J Clin Psychiatry 1996; 57 Suppl 8: 11-16
49. Pranzatelli MR. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Biochem Pharmacol 1991; 42: 1099-1105
50. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 1996; 126: 234-240
51. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990; 51: 51-54
52. Roth BL, Hamblin M, Ciaranello RD. Regulation of 5-HT2 and 5-HT1C serotonin receptor levels. Methodology and mechanisms. Neuropsychopharmacology 1990; 3: 427-433
53. Rowan MJ, Anwyl R. Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine. Eur J Pharmacol 1986; 132: 93-96
54. Sanders-Bush E, Breeding M. Serotoninlc receptor reserve in choroid plexus masks receptor subsensitivity. J Pharmacol Exp Ther 1990; 252: 984-988
55. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 1995; 66: 339-368
56. Seeman P. Receptor Tables, vol. 2: Drug dissociation constants for neuroreceptors and transporters. Toronto, Canada: SZ Research, 1993
57. Skrebuhhova T, Allikmets L, Matto V. [3H]-ketanserin binding and elevated plus-maze behavior after chronic antidepressant treatment in DSP-4 and P-CPA pretreated rats: evidence for partial involvement of 5-HT2A receptors. Methods Find Exp Clin Pharmacol 1999; 21: 483-490
58. Stadel JM, De Lean A, Lefkowitz RJ. Molecular mechanisms of coupling in hormone reseptor - adenylate cyclase systems. Adv Enzymol Relat Areas Mol Biol 1982; 53: 1-43
59. Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003; 72: 2429-2449
60. VanderMaelen CP, Matheson GK, Wilderman RC, Patterson LA. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 1986; 129: 123-130
61. Willins DL, Deuten AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997; 27: 79-82